Patricio Serra-Bellver

Author

The Christie NHS Foundation Trust ORCID

Also Known As

P. Serra-Bellver, Patricio Serra-Bellver

Publications

910

Citations

H-Index

Concepts

All Affiliations

The Christie NHS Foundation Trust University of Manchester The University of Sydney Cancer Research UK Manchester Institute Royal North Shore Hospital

About

Patricio Serra-Bellver is an author at The Christie NHS Foundation Trust specializing in immunology, immunotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	232
2	Immunology	2	2	232
3	Cancer Therapeutics	2	2	232
4	Pharmacology	1	1	31
5	Clinical Epidemiology	1	1	31

Patricio Serra-Bellver

Publications

794

Citations

H-Index

Page 1

	Year	Citations
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, Nature Medicine	2022	397
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, The Lancet Oncology OncologyAnti-pd-1 TherapyMelanomaImmunologyClinical Trials	2021	201
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, Nature Medicine	2024	108
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. Inês Pires da Silva, Tasnia Ahmed, Serigne Lo, Journal of Clinical Oncology Disease ProgressionImmunodeficienciesPrognosisImmunologyPharmacotherapy	2020	31
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study Patricio Serra-Bellver, Judith M. Versluis, H.K. Oberoi, European Journal of Cancer	2022	23
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma Selina K. Wong, Steven M. Blum, Xiaopeng Sun, European Journal of Cancer	2022	14
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities Sharon H. Nahm, Richard Heywood, Sophia Callaghan, European Journal of Cancer	2022	10
Tumour infiltrating B cells discriminate checkpoint blockade-induced responses Sara Valpione, L Campana, John Weightman, European Journal of Cancer	2022	10

Page 1